drugset / Trial / NCT02770625
Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-03
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISU302 | Protein / enzyme biologic | 60 iu/kg | Intravenous |